Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart.

Heart failure stays a significant well being burden around the globe. Despite nice progress in delineation of molecular mechanisms underlying growth of illness, normal remedy has not superior on the similar tempo.

The multifunctional signaling molecule Ca2+/calmodulin-dependent protein kinase II (CaMKII) has acquired appreciable consideration over current years for its central function in maladaptive reworking and arrhythmias in the setting of power illness.

However, these primary science discoveries have but to translate into new therapies for human sufferers. This overview addresses each the promise and boundaries to growing translational therapies that focus on CaMKII signaling to abrogate pathologic reworking in the setting of power illness.

Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart.
Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart.

Efforts in small molecule design are mentioned, in addition to various focusing on approaches that exploit novel avenues for compound supply and/or genetic approaches to have an effect on cardiac CaMKII signaling. These various methods present hope for overcoming some of the challenges which have restricted the event of new therapies.

Carboxy-DCFDA N-succinimidyl ester

GW9790-250 250
EUR 1427.9

Carboxy-DCFDA N-succinimidyl ester

GW9790-50 50
EUR 379.2

Rabbit Anti Human IGHG4 Monoclonal Clone DCF-9

IRBAHUIGHG4DCF9C100UL each
EUR 496
Description: Rabbit Anti Human IGHG4 Monoclonal Clone DCF-9

Desmin (Muscle Cell Marker)(D33), CF647 conjugate, 0.1mg/mL

BNC471722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF647 conjugate, 0.1mg/mL

BNC471722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF568 conjugate, 0.1mg/mL

BNC681722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF568 conjugate, 0.1mg/mL

BNC681722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF594 conjugate, 0.1mg/mL

BNC941722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF594 conjugate, 0.1mg/mL

BNC941722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF647 conjugate, 0.1mg/mL

BNC473069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF647 conjugate, 0.1mg/mL

BNC473069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF405M conjugate, 0.1mg/mL

BNC051722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF405M conjugate, 0.1mg/mL

BNC051722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF640R conjugate, 0.1mg/mL

BNC401722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF640R conjugate, 0.1mg/mL

BNC401722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF568 conjugate, 0.1mg/mL

BNC683069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF568 conjugate, 0.1mg/mL

BNC683069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF488A conjugate, 0.1mg/mL

BNC881722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF488A conjugate, 0.1mg/mL

BNC881722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF405S conjugate, 0.1mg/mL

BNC041722-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Desmin (Muscle Cell Marker)(D33), CF405S conjugate, 0.1mg/mL

BNC041722-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF594 conjugate, 0.1mg/mL

BNC943069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF594 conjugate, 0.1mg/mL

BNC943069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF405S conjugate, 0.1mg/mL

BNC043069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF405S conjugate, 0.1mg/mL

BNC043069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF640R conjugate, 0.1mg/mL

BNC403069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF640R conjugate, 0.1mg/mL

BNC403069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF488A conjugate, 0.1mg/mL

BNC883069-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

Myofibroblast Marker(PR 2D3), CF488A conjugate, 0.1mg/mL

BNC883069-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF647 conjugate, 0.1mg/mL

BNC472843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF647 conjugate, 0.1mg/mL

BNC472843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF647 conjugate, 0.1mg/mL

BNC473075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF647 conjugate, 0.1mg/mL

BNC473075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF568 conjugate, 0.1mg/mL

BNC682843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF568 conjugate, 0.1mg/mL

BNC682843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF568 conjugate, 0.1mg/mL

BNC683075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF568 conjugate, 0.1mg/mL

BNC683075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF594 conjugate, 0.1mg/mL

BNC942843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF594 conjugate, 0.1mg/mL

BNC942843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF594 conjugate, 0.1mg/mL

BNC943075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF594 conjugate, 0.1mg/mL

BNC943075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF405S conjugate, 0.1mg/mL

BNC043075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF405S conjugate, 0.1mg/mL

BNC043075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF640R conjugate, 0.1mg/mL

BNC402843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF640R conjugate, 0.1mg/mL

BNC402843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF640R conjugate, 0.1mg/mL

BNC403075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF640R conjugate, 0.1mg/mL

BNC403075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF488A conjugate, 0.1mg/mL

BNC882843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF488A conjugate, 0.1mg/mL

BNC882843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF488A conjugate, 0.1mg/mL

BNC883075-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

CD44v4/5 (Marker of Tumor Metastasis)(3D2), CF488A conjugate, 0.1mg/mL

BNC883075-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF405S conjugate, 0.1mg/mL

BNC042843-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

SIGLEC1 / CD169 / Sialoadhesin(HSn 7D2), CF405S conjugate, 0.1mg/mL

BNC042843-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF647 conjugate, 0.1mg/mL

BNC470612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF647 conjugate, 0.1mg/mL

BNC470612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF568 conjugate, 0.1mg/mL

BNC680612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF568 conjugate, 0.1mg/mL

BNC680612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF594 conjugate, 0.1mg/mL

BNC940612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF594 conjugate, 0.1mg/mL

BNC940612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF640R conjugate, 0.1mg/mL

BNC400612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF640R conjugate, 0.1mg/mL

BNC400612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF488A conjugate, 0.1mg/mL

BNC880612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF488A conjugate, 0.1mg/mL

BNC880612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF405S conjugate, 0.1mg/mL

BNC040612-100 1uL
EUR 192
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker)(115D8), CF405S conjugate, 0.1mg/mL

BNC040612-500 1uL
EUR 532
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

DCFH-DA [2',7'-Dichlorodihydrofluorescein diacetate] *CAS 4091-99-0*

15204 25 mg
EUR 86

DCFH-DA [2',7'-Dichlorodihydrofluorescein diacetate] *CAS 4091-99-0*

15204-25mg 25 mg
EUR 86
Description: DCFH-DA, 2',7'-Dichlorodihydrofluorescein diacetate (also called 2',7'-dichlorofluorescin diacetate), is hydrolyzed by cellular esterases to 2',7'-dichlorodihydrofluorescein (also called 2',7'-dichlorofluorescin) and is then oxidized to 2',7'-dichlorofluorescein primarily by H2O2.

Leave a Comment